CL2015000418A1 - Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades. - Google Patents

Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.

Info

Publication number
CL2015000418A1
CL2015000418A1 CL2015000418A CL2015000418A CL2015000418A1 CL 2015000418 A1 CL2015000418 A1 CL 2015000418A1 CL 2015000418 A CL2015000418 A CL 2015000418A CL 2015000418 A CL2015000418 A CL 2015000418A CL 2015000418 A1 CL2015000418 A1 CL 2015000418A1
Authority
CL
Chile
Prior art keywords
vegf
psoriasis
peg
diseases
disease
Prior art date
Application number
CL2015000418A
Other languages
English (en)
Spanish (es)
Inventor
Arturo Santos
Phillip Frost
Original Assignee
Opko Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50150466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000418(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc
Publication of CL2015000418A1 publication Critical patent/CL2015000418A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
CL2015000418A 2012-08-21 2015-02-20 Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades. CL2015000418A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691455P 2012-08-21 2012-08-21
US201361791693P 2013-03-15 2013-03-15
US201361862300P 2013-08-05 2013-08-05

Publications (1)

Publication Number Publication Date
CL2015000418A1 true CL2015000418A1 (es) 2015-07-10

Family

ID=50150466

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000418A CL2015000418A1 (es) 2012-08-21 2015-02-20 Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.

Country Status (16)

Country Link
US (2) US10548841B2 (enExample)
EP (1) EP2887958B1 (enExample)
JP (3) JP6336448B2 (enExample)
KR (2) KR102177437B1 (enExample)
CN (1) CN104582728A (enExample)
AR (1) AR092372A1 (enExample)
BR (1) BR112015003658B1 (enExample)
CA (2) CA2879597C (enExample)
CL (1) CL2015000418A1 (enExample)
ES (1) ES2881671T3 (enExample)
HU (1) HUE058912T2 (enExample)
MX (2) MX363822B (enExample)
PL (1) PL2887958T3 (enExample)
RU (1) RU2680096C2 (enExample)
TW (2) TWI683675B (enExample)
WO (1) WO2014031429A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523956A (ja) * 2013-07-11 2016-08-12 ノバルティス アーゲー 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
BR112016013923A2 (pt) * 2013-12-19 2017-08-08 Hoffmann La Roche Modulador de cetp para o uso no tratamento de enfermidade ocular
WO2015168619A1 (en) * 2014-05-02 2015-11-05 Mayo Foundation For Medical Education And Research Individualized treatment of eye disease
KR101778004B1 (ko) 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
WO2017083800A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Occult cnv size as a predictor for treatment with squalamine
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
WO2020041689A1 (en) * 2018-08-23 2020-02-27 Bernstein Eric F Systems, devices and methods for applying anti-vegf compounds and using such compounds to treat skin conditions
CN109180798B (zh) * 2018-09-04 2020-10-27 武汉原生药谷生物医药科技有限公司 一种增强型治疗性抗体及其应用
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
EP3937987A4 (en) * 2019-03-15 2023-06-14 University of Rhode Island Board of Trustees PHLIP ®-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASE TISSUES
WO2020231670A1 (en) 2019-05-16 2020-11-19 Opko Pharmaceuticals, Llc Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
MX2022015656A (es) * 2020-06-15 2023-03-22 Opko Pharmaceuticals Llc Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama.
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN116585304B (zh) * 2023-04-25 2024-04-05 四川大学华西医院 一种急性肝损伤保护药物及其制备方法
IL330178A (en) 2024-01-03 2026-08-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical formulations for delivering active ingredients to the back of the eye
CN119701010B (zh) * 2024-12-25 2025-10-28 山东第一医科大学附属眼科医院(山东省眼科医院) 一种基于中性粒细胞纳米囊泡的抗炎和抗血管双向诱捕联合自发光动力的复合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565861B1 (en) 2000-02-11 2003-05-20 Isis Innovation Limited Artificial tear formulation
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US7785578B2 (en) * 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
WO2007076274A2 (en) * 2005-12-22 2007-07-05 Bausch & Lomb Incorporated Artificial tear solution containing poly (ethylene glycol) peg lipids
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
US8887944B2 (en) * 2007-12-11 2014-11-18 Tokitae Llc Temperature-stabilized storage systems configured for storage and stabilization of modular units
JP5832293B2 (ja) * 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
US20110033527A1 (en) * 2009-06-02 2011-02-10 Nian Wu Opthalmic compositions of cyclosporin
CA2763819A1 (en) 2009-06-02 2010-12-09 Nian WU Pure peg-lipid conjugates
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
KR20120063515A (ko) 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Ｐｉ３ 키나제 억제제 및 이들의 용도

Also Published As

Publication number Publication date
JP2015526467A (ja) 2015-09-10
CN104582728A (zh) 2015-04-29
US11712419B2 (en) 2023-08-01
ES2881671T3 (es) 2021-11-30
RU2015107317A (ru) 2016-10-10
EP2887958A4 (en) 2016-01-20
CA2879597C (en) 2021-01-12
KR102177437B1 (ko) 2020-11-12
CA2879597A1 (en) 2014-02-27
WO2014031429A2 (en) 2014-02-27
JP7098674B2 (ja) 2022-07-11
TW201642838A (zh) 2016-12-16
BR112015003658B1 (pt) 2022-09-27
CA3098856C (en) 2023-10-17
TWI683675B (zh) 2020-02-01
US20200163877A1 (en) 2020-05-28
RU2680096C2 (ru) 2019-02-15
TW201412346A (zh) 2014-04-01
MX2015002233A (es) 2015-07-06
JP2020111589A (ja) 2020-07-27
KR20200023507A (ko) 2020-03-04
HUE058912T2 (hu) 2022-09-28
JP6336448B2 (ja) 2018-06-06
US20150224055A1 (en) 2015-08-13
CA3098856A1 (en) 2014-02-27
US10548841B2 (en) 2020-02-04
MX363822B (es) 2019-04-04
JP2018150329A (ja) 2018-09-27
KR20150042215A (ko) 2015-04-20
EP2887958A2 (en) 2015-07-01
MX2019001021A (es) 2021-11-16
JP6680827B2 (ja) 2020-04-15
EP2887958B1 (en) 2021-05-19
KR102083700B1 (ko) 2020-03-02
WO2014031429A3 (en) 2014-04-24
BR112015003658A2 (pt) 2017-07-04
PL2887958T3 (pl) 2021-11-22
TWI608848B (zh) 2017-12-21
AR092372A1 (es) 2015-04-15

Similar Documents

Publication Publication Date Title
EP2799543A4 (en) HUMANIZED ANTI-EPIREGULIN ANTIBODY AND CANCER THERAPY AGENTS WITH THESE ANTIBODY AS ACTIVE AGENT
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
CL2014000032A1 (es) Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
IL231168B (en) Benzensulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof and their use in the manufacture of medicaments for treating cancer
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
CO6710926A2 (es) Compuestos de n-heteroarilo
CL2016001167A1 (es) Uso de un implante bioerosionable para tratar enfermedades oculares.
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
UY35747A (es) Derivados sustituidos de fenilalanina
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
DOP2016000064A (es) Derivados de fenilalanina sustituidos
CL2014000267A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
UY35745A (es) Derivados sustituidos de fenilalanina